On November 20, Vertex Pharmaceuticals fell 3.01% in Regular Trading, trading at $520.25 per share, with turnover of $252 million.
The clearest recent catalyst is a cluster of insider sales that has pressured near-term sentiment. The latest disclosed filing showed director Sangeeta N. Bhatia sold 271 shares on November 16 for about $148,470, following an earlier sale by EVP and COO/CFO Charles F. Wagner Jr., who sold 15,286 shares on November 12 for about $8.37 million, and a November 6 sale by CEO Reshma Kewalramani of 11,866 shares for about $6.31 million.
These transactions come after a period of supportive fundamentals and analyst optimism, including positive September data for kidney-disease candidate inaxaplin and a November analyst target increase to $640, but the recent pattern of management selling appears to be outweighing those positives in the current session.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)